Membranous nephropathy—one morphologic pattern with different diseases

Pflugers Archiv European Journal of Physiology

Volumn 469, Issue 7-8, 2017, Pages 989-996

  Hoxha, Elion ^a   von Haxthausen, Franziska ^a   Wiech, Thorsten ^a   Stahl, Rolf A K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Membranous nephropathy; PLA2R1; THSD7A

Indexed keywords

MEMBRANE METALLOENDOPEPTIDASE; PHOSPHOLIPASE A2 GROUP I; PHOSPHOLIPASE A2 RECEPTOR; THROMBOSPONDIN 1; THROMBOSPONDIN TYPE 1 DOMAIN CONTAINING 7A; UNCLASSIFIED DRUG; AUTOANTIGEN; PLA2R1 PROTEIN, HUMAN; THROMBOSPONDIN; THROMBOSPONDIN TYPE I DOMAIN CONTAINING 7A PROTEIN, HUMAN;

ANTIGEN RECOGNITION; HUMAN; KIDNEY BIOPSY; KIDNEY DISEASE; MALIGNANT NEOPLASM; MEMBRANOUS GLOMERULONEPHRITIS; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ANIMAL; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY; PATHOLOGY;

ANIMALS; AUTOANTIGENS; DIAGNOSIS, DIFFERENTIAL; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; PODOCYTES; RECEPTORS, PHOSPHOLIPASE A2; THROMBOSPONDINS;

EID: 85019731547     PISSN: 00316768     EISSN: 14322013     Source Type: Journal    
DOI: 10.1007/s00424-017-2000-4     Document Type: Review

References (57)

1. Bacon PA, Tribe CR, Mackenzie JC, Verrier-Jones J, Cumming RH, Amer B (1976) Penicillamine nephropathy in rheumatoid arthritis. A clinical, pathological and immunological study. Q J Med 45:661–684
2. 2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 9:1386–1392
3. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361:11–21
4. Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, Cosio FG, Cattran DC, Salant DJ (2011) Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22:1543–1550
5. Beck LH Jr, Salant DJ (2014) Membranous nephropathy: from models to man. J Clin Invest 124:2307–2314
6. Brzosko WJ, Krawczyński K, Nazarewicz T, Morzycka M, Nowoslawski A (1974) Glomerulonephritis associated with hepatitis-B surface antigen immune complexes in children. Lancet 2:477–482
7. Cahen R, Francois B, Trolliet P, Gilly J, Parchoux B (1989) Aetiology of membranous glomerulonephritis: a prospective study of 82 adult patients. Nephrol Dial Transplant 4:172–180
8. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL (2001) Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 59:1484–1490
9. Combes B, Shorey J, Barrera A, Stastny P, Eigenbrodt EH, Hull AR, Carter NW (1971) Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement me membrane. Lancet 2:234–237
10. Couser WG (2012) Basic and translational concepts of immune-mediated glomerular diseases. J Am Soc Nephrol 23:381–399
11. Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, Michel PA, Mihout F, Dussol B, Matignon M, Mousson C, Simon T, Ronco P, GEMRITUX Study Group (2017) Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol 28:348–358
12. Dähnrich C, Komorowski L, Probst C, Seitz-Polski B, Esnault V, Wetzels JF, Hofstra JM, Hoxha E, Stahl RA, Lambeau G, Stöcker W, Schlumberger W (2013) Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta 421:213–218
13. Debiec H, Guigonis V, Mougenot B, Decobert F, Haymann JP, Bensman A, Deschênes G, Ronco PM (2002) Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 346:2053–2060
14. De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC (2017) A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol 28:421–430
15. Fresquet M, Jowitt TA, Gummadova J, Collins R, O’Cualain R, McKenzie EA, Lennon R, Brenchley PE (2015) Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. J Am Soc Nephrol 26:302–313
16. Gaber LW, Wall BM, Cooke CR (1993) Coexistence of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis and membranous glomerulopathy. Am J Clin Pathol 99:211–215
17. Glassock RJ (2009) Human idiopathic membranous nephropathy—a mystery solved? N Engl J Med 361(1):81–83
18. Gödel M, Grahammer F, Huber TB (2015) Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 372:1073
19. Hladunewich MA, Cattran D, Beck LH, Odutayo A, Sethi S, Ayalon R, Leung N, Reich H, Fervenza FC (2014) A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy. Nephrol Dial Transplant 29:1570–1577
20. Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF (2012) Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 23:1735–1743
21. Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D, Feehally J, Gaskin GJ, Jayne DR, O’Donoghue D, Boulton-Jones M, Mathieson PW (2013) Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 381:744–7451
22. Hoxha E, Beck LH, Wiech T, Tomas NM, Probst C, Mindorf S, Meyer-Schwesinger C, Zahner G, Stahl PR, Schöpper R, Panzer U, Harendza S, Helmchen U, Salant DJ, Stahl RAK (2016) An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy. J Am Soc Nephrol 28:520–531
23. Hoxha E, Harendza S, Pinnschmidt H, Panzer U, Stahl RA (2014) M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol 9:1883–1890
24. Hoxha E, Harendza S, Pinnschmidt H, Panzer U, Stahl RA (2014) PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system. PLoS One 9(10):e110681
25. Hoxha E, Harendza S, Pinnschmidt HO, Tomas NM, Helmchen U, Panzer U, Stahl RA (2015) Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy. Nephrol Dial Transplant 30:1862–1869
26. 2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 26:2526–2532
27. Hoxha E, Kneißler U, Stege G, Zahner G, Thiele I, Panzer U, Harendza S, Helmchen UM, Stahl RA (2012) Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 82:797–804
28. Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl RA (2014) Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol 25:1357–1366
29. Hoxha E, Wiech T, Stahl PR, Zahner G, Tomas NM, Meyer-Schwesinger C, Wenzel U, Janneck M, Steinmetz OM, Panzer U, Harendza S, Stahl RA (2016) A mechanism for cancer-associated membranous nephropathy. N Engl J Med 374:1995–1996
30. Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K, Sakhuja V (2007) A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 18:1899–1904
31. Jones DB (1957) Nephrotic glomerulonephritis. Am J Pathol 33:313–329
32. Kanigicherla D, Gummadova J, McKenzie EA, Roberts SA, Harris S, Nikam M, Poulton K, McWilliam L, Short CD, Venning M, Brenchley PE (2013) Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 83:940–948
33. Kao L, Lam V, Waldman M, Glassock RJ, Zhu Q (2015) Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy. J Am Soc Nephrol 26:291–301
34. Lee JC, Yamauchi H, Hopper J Jr (1966) The association of cancer and the nephrotic syndrome. Ann Intern Med 64:41–51
35. Lhotta K, Wurzner R, Konig P (1999) Glomerular deposition of mannose-binding lectin in human glomerulonephritis. Nephrol Dial Transplant 14:881–886
36. Lv J, Hou W, Zhou X, Liu G, Zhou F, Zhao N, Hou P, Zhao M, Zhang H (2013) Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy. J Am Soc Nephrol 24:1323–1329
37. McCoy RC, Tisher CC (1972) Glomerulonephritis associated with sarcoidosis. Am J Pathol 68:339–358
38. Meyer-Schwesinger C, Lambeau G, Stahl RA (2015) Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 372:1074–1075
39. Mok CC (2009) Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. Nat Rev Nephrol 5:212–220
40. Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, Baltar J, Fernández-Fresnedo G, Martín C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernández-Juárez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernández-Vega F, Praga M, Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología (2010) Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21:697–704
41. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, Melis P, Valzorio B, Sasdelli M, Pasquali S, Pozzi C, Piccoli G, Lupo A, Segagni S, Antonucci F, Dugo M, Minari M, Scalia A, Pedrini L, Pisano G, Grassi C, Farina M, Bellazzi R (1998) A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 9:444–450
42. Praga M, Barrio V, Juárez GF, Luño J (2007) Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int 71:924–930
43. Prunotto M, Carnevali ML, Candiano G et al (2010) Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 21:507–519
44. Qin W, Beck LH Jr, Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z (2011) Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 22:1137–1143
45. Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pellé T, Gaspari F, Suardi F, Gagliardini E, Orisio S, Benigni A, Ronco P, Remuzzi G (2015) Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol 26:2545–2558
46. Saran AM, Yuan H, Takeuchi E, McLaughlin M, Salant DJ (2003) Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy. Kidney Int 64:2072–2078
47. Seitz-Polski B, Dolla G, Payré C, Girard CA, Polidori J, Zorzi K, Birgy-Barelli E, Jullien P, Courivaud C, Krummel T, Benzaken S, Bernard G, Burtey S, Mariat C, Esnault VL, Lambeau G (2016) Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy. J Am Soc Nephrol 27:1517–1533
48. Škoberne A, Behnert A, Teng B, Fritzler MJ, Schiffer L, Pajek J, Lindič J, Haller H, Schiffer M (2014) Serum with phospholipase A2 receptor autoantibodies interferes with podocyte adhesion to collagen. Eur J Clin Investig 44(8):753–765
49. Stahl R, Hoxha E, Fechner K (2010) PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med 363:496–498
50. Stanescu HC, Arcos-Burgos M, Medlar A, Bockenhauer D, Kottgen A, Dragomirescu L, Voinescu C, Patel N, Pearce K, Hubank M, Stephens HA, Laundy V, Padmanabhan S, Zawadzka A, Hofstra JM, Coenen MJ, den Heijer M, Kiemeney LA, Bacq-Daian D, Stengel B, Powis SH, Brenchley P, Feehally J, Rees AJ, Debiec H, Wetzels JF, Ronco P, Mathieson PW, Kleta R (2011) Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 364:616–626
51. Stehlé T, Audard V, Ronco P, Debiec H (2015) Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy. Nephrol Dial Transplant 30:1047–1450
52. Timmermans SA, Ayalon R, van Paassen P, Beck LH Jr, van Rie H, Wirtz JJ, Verseput GH, Frenken LA, Salant DJ, Cohen Tervaert JW, Limburg Renal Registry (2013) Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy. Am J Kidney Dis 62:1223–1225
53. Tomas NM, Beck LH Jr, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, Dolla G, Hoxha E, Helmchen U, Dabert-Gay AS, Debayle D, Merchant M, Klein J, Salant DJ, Stahl RA, Lambeau G (2014) Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 371:2277–2287
54. Tomas NM, Hoxha E, Reinicke AT, Fester L, Helmchen U, Gerth J, Bachmann F, Budde K, Koch-Nolte F, Zahner G, Rune G, Lambeau G, Meyer-Schwesinger C, Stahl RA (2016) Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J Clin Invest 126:2519–2532
55. Tönroth T, Skrifvars B (1974) Gold nephropathy prototype of membranous glomerulonephritis. Am J Pathol 75:573–590
56. Troxell ML, Saxena AB, Kambham N (2006) Concurrent anti-glomerular basement membrane disease and membranous glomerulonephritis: a case report and literature review. Clin Nephrol 66:120–127
57. Yuan H, Takeuchi E, Taylor GA, McLaughlin M, Brown D, Salant DJ (2002) Nephrin dissociates from actin, and its expression is reduced in early experimental membranous nephropathy. J Am Soc Nephrol 13:946–956